Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
Executive Summary
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.
You may also be interested in...
Genetic Testing For Tamoxifen, Warfarin, Plavix Lacks “Clear Value,” Express Scripts Says
Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.